Clinical Trials · NCT04076462
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Camurus AB
- Enrollment
- 72
- Start date
- Aug 2019
- Locations
- 63 sites, 10 countries
- Primary endpoint
- Proportion of Participants With Mean Insulin-like Growth Factor -1 (IGF-1) Levels ≤1 x Upper Limit of Normal (ULN) at Week 22/24